Athelas vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF healthcare tech with remote patient monitoring devices and AI medical billing for CCM/RPM programs; $132M General Catalyst and Sequoia backed generating $200-300/month per patient in additional practice revenue.
About
Athelas is a San Francisco-based healthcare technology company providing remote patient monitoring (RPM) devices and AI-powered medical billing automation for physicians managing patients with chronic conditions — enabling clinics to capture recurring CMS (Centers for Medicare & Medicaid Services) reimbursement for Chronic Care Management (CCM) and Remote Patient Monitoring programs that most practices fail to bill correctly or at all. Founded in 2016 by Tanay Tandon and Deepika Bodapati and backed with $132 million raised from General Catalyst, Sequoia Capital, and others, Athelas serves 1,000+ healthcare provider organizations with cellular-connected monitoring devices and automated billing workflow.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.